Efficacy and safety of hydroxychloroquine for treatment of mild SARS-CoV-2 infection and prevention of COVID-19 severity in pregnant and postpartum women : A randomized, double-blind, placebo-controlled trial
© 2023 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG)..
INTRODUCTION: Pregnant women have an increased risk of severe COVID-19. Evaluation of drugs with a safety reproductive toxicity profile is a priority. At the beginning of the pandemic, hydroxychloroquine (HCQ) was recommended for COVID-19 treatment.
MATERIAL AND METHODS: A randomized, double-blind, placebo-controlled clinical trial was conducted in eight teaching hospitals in Spain to evaluate the safety and efficacy of HCQ in reducing viral shedding and preventing COVID-19 progression. Pregnant and postpartum women with a positive SARS-CoV-2 PCR (with or without mild COVID-19 signs/symptoms) and a normal electrocardiogram were randomized to receive either HCQ orally (400 mg/day for 3 days and 200 mg/day for 11 days) or placebo. PCR and electrocardiogram were repeated at day 21 after treatment start. Enrollment was stopped before reaching the target sample due to low recruitment rate. Trial registration EudraCT #: 2020-001587-29, on April 2, 2020.
CLINICAL TRIALS: gov # NCT04410562, registered on June 1, 2020.
RESULTS: A total of 116 women (75 pregnant and 41 post-partum) were enrolled from May 2020 to June 2021. The proportion of women with a positive SARS-CoV-2 PCR at day 21 was lower in the HCQ group (21.8%, 12/55) than in the placebo group (31.6%, 18/57), although the difference was not statistically significant (P = 0.499). No differences were observed in COVID-19 progression, adverse events, median change in QTc, hospital admissions, preeclampsia or poor pregnancy and perinatal outcomes between groups.
CONCLUSIONS: HCQ was found to be safe in pregnant and postpartum women with asymptomatic or mild SARS-CoV-2 infection. Although the prevalence of infection was decreased in the HCQ group, the statistical power was insufficient to confirm the potential beneficial effect of HCQ for COVID-19 treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:103 |
|---|---|
| Enthalten in: |
Acta obstetricia et gynecologica Scandinavica - 103(2024), 3 vom: 01. Feb., Seite 602-610 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
González, Raquel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 16.02.2024 Date Revised 17.02.2024 published: Print-Electronic ClinicalTrials.gov: NCT04410562 Citation Status MEDLINE |
|---|
| doi: |
10.1111/aogs.14745 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365889075 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365889075 | ||
| 003 | DE-627 | ||
| 005 | 20240217232255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/aogs.14745 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1297.xml |
| 035 | |a (DE-627)NLM365889075 | ||
| 035 | |a (NLM)38098221 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a González, Raquel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of hydroxychloroquine for treatment of mild SARS-CoV-2 infection and prevention of COVID-19 severity in pregnant and postpartum women |b A randomized, double-blind, placebo-controlled trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2024 | ||
| 500 | |a Date Revised 17.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04410562 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG). | ||
| 520 | |a INTRODUCTION: Pregnant women have an increased risk of severe COVID-19. Evaluation of drugs with a safety reproductive toxicity profile is a priority. At the beginning of the pandemic, hydroxychloroquine (HCQ) was recommended for COVID-19 treatment | ||
| 520 | |a MATERIAL AND METHODS: A randomized, double-blind, placebo-controlled clinical trial was conducted in eight teaching hospitals in Spain to evaluate the safety and efficacy of HCQ in reducing viral shedding and preventing COVID-19 progression. Pregnant and postpartum women with a positive SARS-CoV-2 PCR (with or without mild COVID-19 signs/symptoms) and a normal electrocardiogram were randomized to receive either HCQ orally (400 mg/day for 3 days and 200 mg/day for 11 days) or placebo. PCR and electrocardiogram were repeated at day 21 after treatment start. Enrollment was stopped before reaching the target sample due to low recruitment rate. Trial registration EudraCT #: 2020-001587-29, on April 2, 2020 | ||
| 520 | |a CLINICAL TRIALS: gov # NCT04410562, registered on June 1, 2020 | ||
| 520 | |a RESULTS: A total of 116 women (75 pregnant and 41 post-partum) were enrolled from May 2020 to June 2021. The proportion of women with a positive SARS-CoV-2 PCR at day 21 was lower in the HCQ group (21.8%, 12/55) than in the placebo group (31.6%, 18/57), although the difference was not statistically significant (P = 0.499). No differences were observed in COVID-19 progression, adverse events, median change in QTc, hospital admissions, preeclampsia or poor pregnancy and perinatal outcomes between groups | ||
| 520 | |a CONCLUSIONS: HCQ was found to be safe in pregnant and postpartum women with asymptomatic or mild SARS-CoV-2 infection. Although the prevalence of infection was decreased in the HCQ group, the statistical power was insufficient to confirm the potential beneficial effect of HCQ for COVID-19 treatment | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a hydroxychloroquine | |
| 650 | 4 | |a pregnancy | |
| 650 | 4 | |a randomized controlled trial | |
| 650 | 4 | |a women | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 700 | 1 | |a Goncé, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Gil, Mª Del Mar |e verfasserin |4 aut | |
| 700 | 1 | |a Mazarico, Edurne |e verfasserin |4 aut | |
| 700 | 1 | |a Ferriols-Pérez, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Toro, Paloma |e verfasserin |4 aut | |
| 700 | 1 | |a Llurba, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Saéz, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Zambrano, Miguel Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a García-Otero, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a López, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Santacruz, Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Román, Mª Ángeles |e verfasserin |4 aut | |
| 700 | 1 | |a Payà, Antoni |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Cruz-Lemini, Mónica |e verfasserin |4 aut | |
| 700 | 1 | |a Pons-Duran, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Herrera, Luis Bernardo |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Haily |e verfasserin |4 aut | |
| 700 | 1 | |a Bardají, Azucena |e verfasserin |4 aut | |
| 700 | 1 | |a Quintó, Llorenç |e verfasserin |4 aut | |
| 700 | 1 | |a Menendez, Clara |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-Preg research group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta obstetricia et gynecologica Scandinavica |d 1947 |g 103(2024), 3 vom: 01. Feb., Seite 602-610 |w (DE-627)NLM000123765 |x 1600-0412 |7 nnns |
| 773 | 1 | 8 | |g volume:103 |g year:2024 |g number:3 |g day:01 |g month:02 |g pages:602-610 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/aogs.14745 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 103 |j 2024 |e 3 |b 01 |c 02 |h 602-610 | ||